These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 12189927)

  • 21. Why hypertension is so prevalent in the elderly-and how to treat it.
    Chrysant SG; Frohlich ED; Papper S
    Geriatrics; 1976 Oct; 31(10):101-4,108. PubMed ID: 9336
    [No Abstract]   [Full Text] [Related]  

  • 22. [Hypertension and the sympathetic nervous system - recent developments in research and treatment].
    Grisk O
    Dtsch Med Wochenschr; 2009 Nov; 134(45):2289-93. PubMed ID: 19876804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effect of beta-blockers on the cardiac rhythm variability in patients with hypertension].
    Bil'chenko AV
    Lik Sprava; 2002; (1):38-41. PubMed ID: 11944376
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Do most antihypertensive agents have a sympatholytic action?
    de Champlain J
    Curr Hypertens Rep; 2001 Aug; 3(4):305-13. PubMed ID: 11470013
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The involvement of the sympathetic nervous system in tetanus.
    Hörtnagl H; Brücke T; Hackl JM
    Klin Wochenschr; 1979 Apr; 57(8):383-9. PubMed ID: 37368
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Antihypertensive therapy in renal failure].
    Mayer G
    Acta Med Austriaca; 1995; 22(3):51-3. PubMed ID: 8571752
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alpha Adrenergic Blockers in the Treatment of Hypertension--A Nephrologist's Perspective.
    Taraphder A
    J Assoc Physicians India; 2014 Sep; 62(9 Suppl):30-3. PubMed ID: 26245040
    [No Abstract]   [Full Text] [Related]  

  • 28. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications.
    Triposkiadis F; Karayannis G; Giamouzis G; Skoularigis J; Louridas G; Butler J
    J Am Coll Cardiol; 2009 Nov; 54(19):1747-62. PubMed ID: 19874988
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Moxonidine well tolerated and effective in the treatment of viscerally obese, non-controlled hypertensive patients.
    Cardiovasc J S Afr; 2006; 17(4):209. PubMed ID: 17001427
    [No Abstract]   [Full Text] [Related]  

  • 30. [EFFICACY OF ANTIARRHYTHMIC AGENTS UNDER CONDITIONS OF STIMULATION OF THE SYMPATHETIC NERVOUS SYSTEM.].
    Popova EP; Fisenko VP
    Eksp Klin Farmakol; 2016; 79(11):26-34. PubMed ID: 29791106
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Point: Chronic activation of the sympathetic nervous system is the dominant contributor to systemic hypertension.
    Esler M; Lambert E; Schlaich M
    J Appl Physiol (1985); 2010 Dec; 109(6):1996-8; discussion 2016. PubMed ID: 20185633
    [No Abstract]   [Full Text] [Related]  

  • 32. Pharmacological properties of the central antihypertensive agent, moxonidine.
    Edwards LP; Brown-Bryan TA; McLean L; Ernsberger P
    Cardiovasc Ther; 2012 Aug; 30(4):199-208. PubMed ID: 21884003
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of antihypertensive therapy on sympathetic nervous system activity in patients with essential hypertension.
    Chernow B; Zaloga GP; Lake CR; Coleman MD; Ziegler MG
    Fed Proc; 1984 Jan; 43(1):72-7. PubMed ID: 6317467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. Activation of the sympathetic nervous system is the dominant contributor to systemic hypertension.
    Negrao CE; Negrao MV
    J Appl Physiol (1985); 2010 Dec; 109(6):2006. PubMed ID: 21188817
    [No Abstract]   [Full Text] [Related]  

  • 35. The importance of the sympathetic nervous system in hypertension. Introduction.
    van Zwieten PA; Julius S
    J Hypertens Suppl; 1999 Aug; 17(3):S1. PubMed ID: 10489091
    [No Abstract]   [Full Text] [Related]  

  • 36. Possible role of the sympathetic nervous system in the pathogenesis of hypertension.
    Zanchetti A
    J Hypertens Suppl; 1985 Dec; 3(4):S57-9. PubMed ID: 3868712
    [No Abstract]   [Full Text] [Related]  

  • 37. Treatment of hypertension.
    Richardson PJ
    Age Ageing; 1979; Suppl():39-43. PubMed ID: 43078
    [No Abstract]   [Full Text] [Related]  

  • 38. The sympathetic nervous system as a target for the treatment of hypertension and cardiometabolic diseases.
    Sorota S
    J Cardiovasc Pharmacol; 2014 May; 63(5):466-76. PubMed ID: 24805148
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of moxonidine to reduce atrial fibrillation burden in hypertensive patients.
    Deftereos S; Giannopoulos G; Kossyvakis C; Efremidis M; Panagopoulou V; Raisakis K; Kaoukis A; Karageorgiou S; Bouras G; Katsivas A; Pyrgakis V; Stefanadis C
    Am J Cardiol; 2013 Sep; 112(5):684-7. PubMed ID: 23726175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Initial therapy for hypertension.
    Frohlich ED
    Hosp Pract (Off Ed); 1987 May; 22(5):89-96. PubMed ID: 2883192
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.